Irisin in elderly people with hypertension, diabetes mellitus type 2, and overweight and obesity

  • Xiaorong Guo
  • Xianfa Xuan
  • Bin Zhao
  • Yehong Wang
  • Shaoying Zhong
  • Yanhua Su
  • Xiaoshan Yu
  • Qijun Cheng
  • Zeyu Zhao
  • Yuxin WangEmail author
  • Benhua ZhaoEmail author
Original Article



This study aimed to investigate the irisin levels in elderly patients with hypertension, diabetes mellitus type 2, and overweight and obesity, to investigate the possible association between irisin levels and anthropometric and biochemical parameters, and also to assess the irisin levels associated with a risk of hypertension, diabetes mellitus type 2, and overweight and obesity.


A nested case-control study was conducted, with hypertension, diabetes mellitus type 2, and overweight and obesity being set as the case group; 71 elderly patients from the cohort were enrolled in each case group, and 71 healthy elderly from the cohort were included in the control group. The anthropometric and biochemical parameters were measured in all elderly, and irisin levels were measured using enzyme-linked immunosorbent assay.


The irisin levels were significantly lower in patients with hypertension, diabetes mellitus type 2, and overweight and obesity than in controls (p < 0.001). Irisin levels were negatively correlated with body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, cholesterol, triglyceride, and alanine aminotransferase. Moreover, the model adjusted for body mass index, systolic blood pressure, diastolic blood pressure, and fasting blood glucose showed that increasing irisin levels were associated with a reduced risk of hypertension, diabetes mellitus type 2, and overweight and obesity. Receiver operating characteristic curve analysis showed that the area under the curve was 0.779 for hypertension, 0.976 for diabetes mellitus type 2, and 0.957 for overweight and obesity.


Irisin may thus play a role in blood pressure and blood glucose regulation.


Irisin T2DM Hypertension Overweight and obesity Cardiovascular 



We are grateful to all the study subjects for their participants.

Funding information

This work was supported by the Fujian Science and Technology Project Induction Project (2018D0009) and the undergraduate program of basic innovation research fund of Xiamen University (2017X0050, 2017Y0077).

Compliance with ethical standards

The study were approved by the ethics committee of School of Public health, Xiamen University. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.

Competing interests

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    National Health and Family Planning Commission of the People’s Republic of China, The fifth national health services survey analysis report, 2016, Acessed 20 Oct 2017
  2. 2.
    Chen W, Gao R, Liu L, et al. Cardiovascular disease report in China. Chin Circ J. 2017;1(33):1–8.Google Scholar
  3. 3.
    Yang F, Qian D, Hu D, et al. Prevalence of cardiovascular disease risk factor clustering in Chinese adults. Clin Trial Regul Sci Cardiol. 2016;3(15)):1–6.Google Scholar
  4. 4.
    Byeon CH, Kang KY, Kang SH, Bae EJ. Sarcopenia is associated with Framingham risk score in the Korean population: Korean National Health and Nutrition Examination Survey (KNHANES) 2010–2011. J Geriatr Cardiol. 2015;12:366–72.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. Trends Endocrinol Metab. 2016;27:335–47.CrossRefGoogle Scholar
  6. 6.
    Giudice J, Taylor JM. Muscle as a paracrine and endocrine organ. Curr Opin Pharmacol. 2017;6(34):49–55.CrossRefGoogle Scholar
  7. 7.
    Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–8.CrossRefGoogle Scholar
  8. 8.
    Hofmann T, Elbelt U, Stengel A. Irisin as a muscle-derived hormone stimulating thermogenesis–a critical update. Peptides. 2014;54:89–100.CrossRefGoogle Scholar
  9. 9.
    Zhang H-J, Zhang X-F, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013;59(3):557–62.CrossRefGoogle Scholar
  10. 10.
    Shanaki M, Moradi N, Emangholipour S, et al. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab Syndr Clin Res Rev. 2017;11:467–72.CrossRefGoogle Scholar
  11. 11.
    Roca-Rlvadai A, Castelao C, Senn LL, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013;8(4):e60563.CrossRefGoogle Scholar
  12. 12.
    Celik HT, Akkaya N, Erdamar H, et al. The effects of valsartan and amlodipine on the levels of Irisin, Adropin, and Perilipin. Clin Lab. 2015;61(12):1889–95.PubMedGoogle Scholar
  13. 13.
    Fu J, Han Y, Wang J, et al. Irisin lowers blood pressure by improvement of endothelial dysfunction via AMPK-Akt-eNOS-NO pathway is the spontaneously hypertensive rat. Am Heart Assoc. 2016;5(11):e003433.Google Scholar
  14. 14.
    Jang HB, Kim H-J, Kang JH, Park SI, Park KH, Lee H-J. Association of circulating irisin levels with metabolic and metabolite profiles of Korean adolescents. Metab Clin Exp. 2017;73:100–8.CrossRefGoogle Scholar
  15. 15.
    Catli G, Kume T, Hu T, et al. Relation of serum irisin level with metabolic and anthropometric parameters in obese children. J Diabetes Complicat. 2016;30(8):1560–5.CrossRefGoogle Scholar
  16. 16.
    Palacios-Gonzalez B, Vadillo-Ortege F, Pob-Oteyza E, et al. Irisin levels before and after physical activity among school-age children with different BMI: a direct relation with leptin. Obesity (Silver Spring). 2015;23(4):729–32.CrossRefGoogle Scholar
  17. 17.
    Zhang Y, Sun Y, Ding S-Z. The novel myokine-irisin. Chin J Biochem Mol Biol. 2017;33(5):429–35.Google Scholar
  18. 18.
    Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2014;63(2):207–17.CrossRefGoogle Scholar
  19. 19.
    Rizk FH, Elshweikh SA, Abd EI-Naby AY. Irisin levels in relation to metabolic and liver functions in Egyptian patients with metabolic syndrome. Can J Physiol Pharmacol. 2016;94(4):359–62.CrossRefGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2020

Authors and Affiliations

  1. 1.State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public HealthXiamen UniversityXiamenPeople’s Republic of China
  2. 2.Department of NephrologyThe Second Affiliated Hospital of Xiamen Medical CollegeXiamenPeople’s Republic of China
  3. 3.Laboratory Department, State Key Laboratory of Molecular Vaccinology and Molecular DiagnosticsXiang’an Hospital of Xiamen UniversityXiamenPeople’s Republic of China
  4. 4.Department of Physical ExaminationXiamen Lianhua HospitalXiamenPeople’s Republic of China
  5. 5.Department of Obstetrics and GynecologyXiamen Lianhua HospitalXiamenPeople’s Republic of China

Personalised recommendations